Edwards Lifesciences (EW) stock faces a downgrade at Wolfe due to concerns over its TAVR market prospects. Read more here.

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...

Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

Edwards Lifesciences Corp. engages in the patient ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter ...

The US Supreme Court rejected a case asking the justices to interpret a patent-infringement safe-harbor provision in a ...

Capital Investment Advisors LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.4% during the fourth quarter, according to its most recent disclosure with the ...

Harbor Capital Advisors Inc. boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.5% during the 4th quarter, according to its most recent disclosure with the ...

In a report released yesterday, Lee Hambright from Bernstein maintained a Hold rating on Edwards Lifesciences (EW – Research Report). The ...

Daniel J. Lippis, the Corporate Vice President for JAPAC at Edwards Lifesciences Corp (NYSE:EW), has disclosed recent stock ...

Following these transactions, Bobo holds 46,935.7184 shares directly, with additional holdings in indirect accounts, ...

The Rockets' two top scorers have a chance to be voted into the NBA All-Star Game, recognition their teammates say both ...